Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2025)
Keros Therapeutics (KROS) posted Total Current Liabilities of $20.4 million for Q4 2025, down 15.27% on a QoQ basis from $24.1 million in Q3 2025, and down 25.63% year-over-year from $27.4 million in Q4 2024.
Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2025) Analysis & Trends
Keros Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $20.4 million for Q4 2025.
- Quarterly Total Current Liabilities fell 25.63% year-over-year to $20.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.4 million (down 25.63% YoY) and the FY2025 annual result came in at $20.4 million, down 25.63% from the prior year.
- Total Current Liabilities was $20.4 million for Q4 2025 at Keros Therapeutics, down from $24.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $39.4 million in Q1 2025 and bottomed at $7.5 million in Q2 2021.
- A 5-year average of $19.1 million and a median of $16.6 million in 2022 frame the typical range for Total Current Liabilities.
- Peak annual rise in Total Current Liabilities reached 110.38% in 2025, while the deepest fall reached 25.63% in 2025.
- Keros Therapeutics' Total Current Liabilities stood at $11.8 million in 2021, then surged by 39.68% to $16.5 million in 2022, then soared by 47.3% to $24.4 million in 2023, then gained by 12.62% to $27.4 million in 2024, then dropped by 25.63% to $20.4 million in 2025.
- Business Quant data shows KROS's Total Current Liabilities at $20.4 million in Q4 2025, $24.1 million in Q3 2025, and $34.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | 20.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.41 Mn |
| Sep 30, 2025 | 24.09 Mn |
| Jun 30, 2025 | 34.71 Mn |
| Mar 31, 2025 | 39.38 Mn |
| Dec 31, 2024 | 27.45 Mn |
| Sep 30, 2024 | 29.01 Mn |
| Jun 30, 2024 | 21.25 Mn |
| Mar 31, 2024 | 18.72 Mn |
| Dec 31, 2023 | 24.37 Mn |
| Sep 30, 2023 | 16.70 Mn |
| Jun 30, 2023 | 16.10 Mn |
| Mar 31, 2023 | 15.46 Mn |
| Dec 31, 2022 | 16.55 Mn |
| Sep 30, 2022 | 11.53 Mn |
| Jun 30, 2022 | 15.45 Mn |
| Mar 31, 2022 | 11.65 Mn |
| Dec 31, 2021 | 11.85 Mn |
| Sep 30, 2021 | 11.02 Mn |
| Jun 30, 2021 | 7.53 Mn |
| Mar 31, 2021 | 8.95 Mn |